Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD)
Charlotte M. Pretzsch, Bogdan Voinescu, María Andreina Méndez, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 9, pp. 1141-1148
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

The Polypharmacological Effects of Cannabidiol
Jorge Iván Castillo-Arellano, Ana Canseco-Alba, Stephen J. Cutler, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3271-3271
Open Access | Times Cited: 73
THC and CBD: Similarities and differences between siblings
Nephi Stella
Neuron (2023) Vol. 111, Iss. 3, pp. 302-327
Open Access | Times Cited: 59
Review: Cannabinoids as Medicinals
Jag Khalsa, Gregory Bunt, Kenneth Blum, et al.
Current Addiction Reports (2022) Vol. 9, Iss. 4, pp. 630-646
Open Access | Times Cited: 44
The therapeutic potential of purified cannabidiol
Saoirse E. O’Sullivan, Sanne Jensen, Gitte Nykjaer Nikolajsen, et al.
Journal of Cannabis Research (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 29
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Inga Dammann, Cathrin Rohleder, F. Markus Leweke
Pharmacopsychiatry (2024) Vol. 57, Iss. 03, pp. 115-132
Closed Access | Times Cited: 13
Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders
Olivier J. Manzoni, Antonia Manduca, Viviana Trezza
Trends in Pharmacological Sciences (2025)
Open Access | Times Cited: 1
Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies
Laura Fusar‐Poli, Vito Cavone, Silvia Tinacci, et al.
Brain Sciences (2020) Vol. 10, Iss. 9, pp. 572-572
Open Access | Times Cited: 66
The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
Vincenzo Di Marzo
Dialogues in Clinical Neuroscience (2020) Vol. 22, Iss. 3, pp. 259-269
Open Access | Times Cited: 62
Cannabis and cannabinoid use in autism spectrum disorder: a systematic review
Estácio Amaro da Silva Júnior, Wandersonia Moreira Brito Medeiros, Nelson Torro Alves, et al.
Trends in Psychiatry and Psychotherapy (2021)
Open Access | Times Cited: 54
A scoping review of the use of cannabidiol in psychiatric disorders
Anna E. Kirkland, Matthew C. Fadus, Staci A. Gruber, et al.
Psychiatry Research (2021) Vol. 308, pp. 114347-114347
Open Access | Times Cited: 48
FMR1 and Autism, an Intriguing Connection Revisited
William Fyke, Milen Velinov
Genes (2021) Vol. 12, Iss. 8, pp. 1218-1218
Open Access | Times Cited: 42
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
João Francisco Cordeiro Pedrazzi, Frederico Rogério Ferreira, Danyelle Silva-Amaral, et al.
Psychopharmacology (2022) Vol. 239, Iss. 9, pp. 2713-2734
Closed Access | Times Cited: 32
A systematic review of cannabidiol trials in neurodevelopmental disorders
Nina-Francecsa Parrella, Aron T. Hill, Peter G. Enticott, et al.
Pharmacology Biochemistry and Behavior (2023) Vol. 230, pp. 173607-173607
Open Access | Times Cited: 18
Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment
Joseph Palumbo, Brian F. Thomas, Dejan B. Budimirovic, et al.
Journal of Neurodevelopmental Disorders (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 17
Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries
Mackenzie M. Aychman, David L. Goldman, Joshua S. Kaplan
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 17
Endocannabinoid System Changes throughout Life: Implications and Therapeutic Potential for Autism, ADHD, and Alzheimer’s Disease
Kamila Gabrieli Dallabrida, Jeane Maria de Oliveira, Ellen Schavarski Chade, et al.
Brain Sciences (2024) Vol. 14, Iss. 6, pp. 592-592
Open Access | Times Cited: 6
Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy
Charlotte M. Pretzsch, Bogdan Voinescu, David J. Lythgoe, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 50
A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019
Sebastian Jugl, Aimalohi Okpeku, Brianna Costales, et al.
Medical Cannabis and Cannabinoids (2021) Vol. 4, Iss. 1, pp. 21-42
Open Access | Times Cited: 39
Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation
Francesca Baratta, Irene Pignata, Lorenzo Ravetto Enri, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 27
Therapeutic potential of CBD in Autism Spectrum Disorder
João Francisco Cordeiro Pedrazzi, Lucas Hassib, Frederico Rogério Ferreira, et al.
International review of neurobiology (2024), pp. 149-203
Closed Access | Times Cited: 5
Uso da Cannabis medicinal e autismo
Maria Clea Marinho Lima, Marcelo Moraes Valênça, Carlos Eduardo Machado, et al.
Jornal Memorial da Medicina (2020) Vol. 2, Iss. 1, pp. 5-14
Closed Access | Times Cited: 34
The Current View on the Paradox of Pain in Autism Spectrum Disorders
Olena V. Bogdanova, Volodymyr B. Bogdanov, Adrien Pizano, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 21
Possible therapeutic applications of cannabis in the neuropsychopharmacology field
Javier Fernández‐Ruíz, Ismael Galve‐Roperh, Onintza Sagredo, et al.
European Neuropsychopharmacology (2020) Vol. 36, pp. 217-234
Closed Access | Times Cited: 30
Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder
Erin A. Henneberry, Martine Lamy, Kelli C. Dominick, et al.
Journal of Autism and Developmental Disorders (2021) Vol. 51, Iss. 12, pp. 4370-4394
Closed Access | Times Cited: 27
CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature
Serap Bilge, Barış Ekici
Journal of Cannabis Research (2021) Vol. 3, Iss. 1
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top